Note : Image shown for reference purposes only. Actual product appearance may vary. Please read product description for full and accurate details

GoodSense Tussin DM Cough & Chest Congestion 20 Mg/200 Mg 4 Oz Rasp - Potential Constraints through 2024

In stock
SKU
MPSPERR-LP72526
More Information
Brand Perrigo
MPN LP72526
Packaging 48/case
$98.42

Details

Compare to Robitussin Cough + Chest Congestion DM active ingredients

Tussin DM Adult Cough Suppressant and Expectorant, Temporarily Relieves Cough, Chest Congestion and Mucus, Raspberry Flavor, for Ages 12 and Over, 4 Fluid Ounces/each count, (48 units/case count)

 

About the product

  • ACTIVE INGREDIENTS: This product contains dextromethorphan HBr (a cough suppressant) and guaifenesin (expectorant) which compare to the active ingredients in Robitussin Cough + Chest Congestion DM.
  • COUGH SUPPRESSANT: GoodSense Tussin DM temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold.
  • EXPECTORANT: Helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes for mucus relief and chest congestion relief.
  • EFFECTIVE COLD RELIEF: GoodSense Tussin DM provides soothing action that targets the source of your cough, plus relieves your chest congestion.
  • NON-DROWSY: When taken as directed, this cough suppressant and expectorant provides mucus relief and is formulated to be a non-drowsy solution for cough and mucus.

Specifications

Compare To
Compare to Robitussin Cough + Chest Congestion DM active ingredients
Active Ingredients
Dextromethorphan HBr, USP 20 mg; Guaifenesin, USP 200 mg
Item Size 4 OZ
Case Pack Quantity 48
Case UPC 50301131725264
Case Dimensions 17 X 12.8 X 5.5
Case Weight 18.5
Case Pack Inner Quantity 6
Cases Per Pallet 56
Ti/Hi 8 x 7
Cube 0.69
Item UPC Code 301131725269
Product Dimensions 2.03 X 2.0 X 5.12
Inner Pack UPC NONE
NDC 0113-1725-26
National Brand UPC 300318736128
Write Your Own Review
You're reviewing:GoodSense Tussin DM Cough & Chest Congestion 20 Mg/200 Mg 4 Oz Rasp - Potential Constraints through 2024
Your Rating
Top